Eisai (4523) investor relations material

Long-term vision and strategic direction

• Aims to make Alzheimer's disease a curable condition by integrating biomarkers, data technology, and drug discovery, focusing on early detection and intervention across the AD continuum.

• Targets sustainable growth by prioritizing LEQEMBI, LENVIMA, and DAYVIGO, while expanding neurology and oncology pipelines and transforming into a distinctive drug discovery company.

• Plans to leverage non-drug R&D and ecosystem platforms, including digital health and elderly care solutions, to address patient anxieties and generate new revenue streams.

• Will annually update and roll forward the three-year plan to adapt to changing business environments and ensure flexibility.

• Emphasizes strengthening management foundations through cost reforms, global structure optimization, and new financial policies to enhance sustainable corporate value.

Financial targets and capital allocation

• Sets FY2028 targets of JPY 1 trillion in revenue and JPY 90 billion in core operating profit, focusing on organic growth and improved profitability.

• Projects cost of sales at JPY 300 billion (30% ratio), R&D expenses at JPY 170 billion, and SG&A at JPY 440 billion for FY2028.

• Introduces core operating profit and adjusted ROIC (targeting 9%) as new performance indicators, aiming for 8%-10% ROIC mid-to-long term.

• Plans JPY 1 trillion investment over three years: JPY 500 billion in in-house R&D and JPY 500 billion in pipeline enhancement, with flexible M&A consideration.

• Diversifies financing sources, including a JPY 50 billion domestic bond issuance, and strengthens balance sheet management with targets for net DER within 0.3 and net debt/EBITDA within 3x.

Product and pipeline development

• LEQEMBI expected to reach JPY 300 billion in sales by FY2028, becoming standard of care in AD; DAYVIGO targets JPY 100 billion, LENVIMA JPY 250 billion, with LENVIMA U.S. exclusivity until at least July 2030.

• Advances next-generation neurology assets (etalanetug, ledasorexton, E2511) and expands oncology pipeline, focusing on MRD in solid tumors and new indications.

• Utilizes AI, molecular profiling, and proprietary biomarkers to enhance drug discovery success and clinical trial efficiency.

• Develops brain-penetrant antibody technology and small molecule platforms, including molecular glue, to address CNS and oncology targets.

• Strengthens external collaborations and in-licensing to accelerate pipeline growth and regulatory submissions, with multiple projects advancing toward FY2028 submissions.